Immunodermatology News

Significant differences in perceived risk factors for systemic disease along with other substantial differences exist in screening and treating children with discoid lupus erythematosus within and across dermatology and rheumatology, Lisa M. Arkin, MD, and colleagues found.

A group of international researchers writing in Pediatric Rheumatology have proposed a plan for tapering and discontinuing glucocorticoids in patients with juvenile-onset dermatomyositis, based on changes in core set measures of disease activity in the first 6 months of treatment.

Researchers were unable to identify the most effective antibiotic treatment for cellulitis, as no one antibiotic was superior over another based on available clinical trial data, according to researchers in JAMA Dermatology.

In adults with atopic dermatitis, treatment with cyclosporine or methotrexate appears to have a lower rate of serious infections than mycophenolate, azathioprine and systemic prednisone, according to a study.

In a paper recently published in Journal of the American Academy of Dermatology, researchers proposed there is a three-part pathogenesis of acute inflammatory edema, a form of pseudocellulitis commonly seen in critically ill patients.

Biological pathways are disrupted among patients with hidradenitis suppurativa, which suggests that inflammatory pathways, pathways of leucocyte activation and signaling, and innate immune responses require more study, according to researchers.

DESTIN, Fla. — In a session here at Congress of Clinical Rheumatology, Joseph F. Merola, MD, MMSc, of Harvard Medical School and Brigham and Women’s Hospital, shared the dermatology approach to cutaneous lupus erythematosus, as well as valuable skin elements of dermatomyositis.

AbbVie announced that the FDA has approved Skyrizi, an interleukin-23 inhibitor for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Among patients with juvenile dermatomyositis, calcinosis was associated with longer active disease duration, disease severity and clinical features such as lipodystrophy and joint contractures, according to data published in Pediatric Rheumatology.

The FDA awarded more than $18 million in grants over the next 4 years to fund clinical trials of medical products intended to treat patients with rare diseases.